Table 4.
Clinically relevant exosomal nucleic acid markers for breast cancer
| RNA/DNA | Source | Detection method |
Patient stages and numbers | Application | Diagnostic value/outcome | Ref. |
|---|---|---|---|---|---|---|
| miR-105 | Serum | RT-qPCR | Pre-metastatic and metastatic stage (n=75) | Detection and diagnosis | P = 0.04 | 82 |
| miR-105 and miR-181a | Serum | RT-qPCR | Stage II, III (n=38) | Diagnosis | P < 0.01 | 82 |
| miR-101, miR-372 and miR-373 | serum | TaqMan MicroRNA assays | Invasive breast cancer (n=50) | Diagnosis | miR-373 -- higher in triple negative, estrogen-negative and progesterone-negative tumors | 84 |
| miR-1246 and miR-21 | Plasma | RT-qPCR | Breast cancer (n=16) | Detection | The AUC for miR-21 was 0.69 (95 % CI 0.50, 0.88; p = 0.048) and for miR-1246 was 0.69 (95 % CI 0.49, 0.89; p = 0.068) | 131 |
| ssODNs | Plasma | ADAPT | Patients with positive breast cancer biopsy (n=59) | Diagnosis | P<0.05 | 132 |
| miR-340-5p, miR-17-5p miR- 130a-3p, miR-93-5p | Plasma | PCR array | Recurrent (n=16) | Prognosis and recurrence | P<0.05 | 85 |
| NANOG NEUROD1 HTR7 KISS1R HOXC | Plasma | PCR array | With or without first relapse and death (n=173) | Prognosis | P<0.05 | 133 |
| LncRNA RP11-445H22.4 | Serum | qRT-PCR | Breast cancer (n=68) | Prognosis | p < 0.001, sensitivity was 92% and specificity was 74 % | 87 |